Sector News

Ablynx announces board changes

February 7, 2018
Life sciences

Ablynx NV today announced that Dr Bo Jesper Hansen, acting as permanent representative of Orfacare Consulting GmbH, has decided to resign from the Board of Directors with immediate effect for personal reasons.

Having contributed to Ablynx’s recent M&A activities, and served on the Board since 2013, Dr Hansen will now focus on other opportunities. He will be succeeded by Dr Russell G. Greig, acting as a permanent representative of Greig Biotechnology Global Consulting Inc., who has been a non-executive Director of Ablynx since 2012, and has been unanimously elected by the Ablynx Board as the new Chairman.

Dr Greig is an industry veteran and is currently Chairman of AM Pharma and MedEye (The NL), Sanifit (Spain and the USA), eTheRNA (Belgium), and a non-executive Director of TiGenix (Belgium). Following a 28-year career at GSK where he held the positions of President of both GSK Pharmaceuticals International and SROne (the Venture Arm of GSK), Dr Greig has served as Chairman of Novagali (sold to Santen), Isconova (to Novavax), Syntaxin (to Ipsen), and as a Venture Partner at Kurma Life Sciences (France).

Dr Edwin Moses, Chief Executive Officer at Ablynx, commented: “We are very fortunate to have a very suitable successor for Bo Jesper, allowing for an orderly transition at this time. Russell knows the company extremely well and will be an important asset during the next months.”

Dr Russell Greig, commented: “I am delighted to accept this position, having worked with the Ablynx Board over the past five years. My goal will be to fully support the proposed acquisition of the Company by Sanofi as recommended by the Ablynx Board.”

From 7 February 2018, the composition of the Board of Ablynx is as follows:
• Russell Greig, Chairman of the Board, acting as permanent representative of Greig Biotechnology Global Consulting Inc.
• Edwin Moses, Director and Chief Executive Officer
• William Jenkins, Independent Director, acting as principal of William Jenkins Pharma Consulting
• Catherine Moukheibir, Independent Director
• Remi Vermeiren, Independent Director
• Lutgart Van den Berghe, Independent Director, acting as permanent representative of NV Feadon
• Hilde Windels, Independent Director, acting as permanent representative of Hilde Windels BVBA

Source: Ablynx

comments closed

Related News

January 23, 2022

UCB to acquire Zogenix

Life sciences

UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

January 23, 2022

argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis

Life sciences

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).

January 23, 2022

GlaxoSmithKline rejects Unilever’s $68B consumer health buyout offer, but a bigger bid is brewing

Life sciences

GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.

Send this to a friend